Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This abstract describes the IV Trichology Congress held in Buenos Aires in September 2023, with over 180 in-person and 450 virtual attendees from various Latin American countries, but does not report specific study results or findings.

This clinical trial found that topical application of Sandalore® 1% significantly reduced hair shedding and increased hair volume in women with telogen effluvium compared to placebo.

This study found that incorporating Argania spinosa kernel oil and/or Theobroma grandiflorum seed butter into hair care formulations reduced protein loss in Caucasian hair dyed with an oxidative product.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

This study evaluated various herbal combinations for hair coloring and found that a formulation of Henna and Indigo provided a natural reddish-brown color with better retention compared to marketed herbal hair dyes, without using synthetic agents that can cause allergic reactions.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

In a study on female Wistar rats, researchers found that a hair tonic containing a 7.5%:2% combination of talok and pare leaf extracts increased hair growth comparable to minoxidil, showing similar efficacy in promoting hair growth without significant statistical difference.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This study found that creambath preparations with waru leaf extract accelerated hair growth in New Zealand White rabbits, though none matched the positive control; the 37.5% concentration increased hair weight effectively.

This study found that inoculating Arabidopsis thaliana seedlings with the rhizobacterium Azospirillum brasilense significantly increased root hair length compared to non-inoculated controls.

This review discusses the diverse bioactivities and potential applications of Halocnemum strobilaceum but reports no new experimental findings.

This study reported that a topical hair tonic containing a 7.5% talok leaf and 2% pare leaf extract combination promoted hair growth in female Wistar rats similarly to minoxidil, showing a 64.71% increase in hair growth with no significant difference from minoxidil in statistical analysis.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This case study reports a young male with alopecia universalis experienced significant hair whitening following baricitinib treatment, highlighting the need for further research on JAK inhibitors' impact on hair pigmentation and their underlying mechanisms.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This study found that fruit extracts from certain Egyptian Sabal species demonstrated significant anti-androgenic activity and potential therapeutic effects against benign prostatic hyperplasia in rat models and cell lines.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This study found that ethanol and water extracts of Albizia saponaria bark significantly stimulated hair growth in male rabbits over 24 days.